Capricor Therapeutics Announces Positive Type-B Meeting With FDA for Cap-1002 Program for Duchenne Muscular Dystrophy
Capricor Therapeutics宣佈與美國食品藥品管理局就杜興氏肌肉萎縮症Cap-1002計劃舉行B型會議
Capricor Therapeutics Announces Positive Type-B Meeting With FDA for Cap-1002 Program for Duchenne Muscular Dystrophy
Capricor Therapeutics宣佈與美國食品藥品管理局就杜興氏肌肉萎縮症Cap-1002計劃舉行B型會議
使用瀏覽器的分享功能,分享給你的好友吧